Gilead Sciences has agreed to acquire Ouro Medicines for up to $2.175 billion to secure its advanced T-cell engager therapies. This strategic buyout reflects a growing industry trend of repurposing oncology technologies to treat severe autoimmune diseases.
Published on March 24
Gilead's $2.175 billion deal to acquire Ouro Medicines isn't just big news — it's a clear sign that pharmaceutical giants are placing massive bets on this space. When the industry's biggest players start writing cheques of this size, it pays to pay attention.
Smaller biotech companies developing T-cell engagers and bispecific antibodies are increasingly on the radar of cash-rich pharmaceutical acquirers. Being invested before a buyout announcement could mean capturing significant upside in a short space of time.
These companies aren't starting from scratch — they're repurposing cancer-fighting technologies that have already shown results in clinical settings. That means less foundational risk and more potential for faster breakthroughs in autoimmune treatment.
Gilead Sciences's $2.175 billion acquisition of Ouro Medicines signals a powerful industry shift: the world's biggest drugmakers are taking cutting-edge cancer-fighting technologies and adapting them to treat severe autoimmune diseases. This opens up enormous new markets and creates fresh opportunities for investors looking to get ahead of a rapidly growing trend in modern medicine.
This group spans a broad mix of clinical-stage biotech companies and established pharmaceutical acquirers, all connected by one theme: repurposing oncology science for autoimmune conditions. These are typically higher-growth, higher-potential stocks. Some are smaller innovative startups that could become acquisition targets, while others are larger, cash-rich companies actively making strategic deals.
Every stock in this group was hand-picked by professional analysts to capture the momentum behind this M&A-driven trend. From companies engineering bispecific antibodies to those pioneering CAR-T cell therapies for autoimmune diseases, each one plays a distinct role in this evolving space. They were selected for their strategic positioning, therapeutic innovation, and potential to benefit from ongoing industry consolidation.
Total market capitalisation is $190.22B, and the basket is heavily anchored by one large-cap holding representing roughly 90% of the total.
GILD: $170.47B
IMVT: $4.96B
AUPH: $1.94B
Get the full story on this Basket. Read our detailed article on its risks and potential.
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
Disney is suing the FCC to block an early license review of its ABC stations, arguing the move is politically motivated retaliation against its news coverage. This unprecedented legal battle highlights the growing regulatory risks for traditional broadcasters and underscores the structural advantages of unregulated digital streaming platforms.
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
Home Depot's recent earnings beat highlights consistent consumer spending on smaller household repair and maintenance projects. This ongoing trend presents promising opportunities for various home improvement retailers and building material suppliers.
+6
Here are a few of the assets in this group. Create an account to unlock the full list.
GILEAD SCIENCES INC
GILD
Current Price
$148.57
Gilead Sciences is acquiring Ouro Medicines to secure advanced T-cell engager therapies, driving its strategic push into treating severe autoimmune di...
Gilead Sciences is acquiring Ouro Medicines to secure advanced T-cell engager therapies, driving its strategic push into treating severe autoimmune diseases.
Join Nemo FREE today and unlock every stock
It only takes 60 seconds.
Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitive Ltd.
If you invested across these assets:
In 12 months it might be worth:
+92.84%
On average, analysts expect assets in this group to grow 92.84% over the next year.
15 of 16 assets in this group are rated Buy by professional analysts.
